NR565
OBJECTIVE ASSESSMENT - EXAM
NR565 Midterm Exam Review:
Advanced Pharmacology Care
of the Fundamentals
Questions and Answers (2026/2027) (Verified Answers) - Chamberlain
50 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
o Pharmacokinetics & Dynamics o Infectious Disease Therapy
o Cardiovascular Pharmacology o Neuropsychiatric Pharmacology
o Endocrine & Metabolic Agents o Pain Management Principles
COVER PAGE - 1
,SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q10 | NR565 2026/2027
SECTION 1
Q1 Question 1 of 50
A 68-year-old male with chronic kidney disease (CrCl 28 mL/min) is prescribed gentamicin for a
severe gram-negative infection. The prescriber asks the nurse practitioner to determine the
appropriate dosing interval adjustment based on altered pharmacokinetics.
A. Increase the dose and extend the interval to maintain therapeutic peak and trough levels.
B. Maintain the standard dose but shorten the interval to compensate for reduced clearance.
C. Switch to oral administration to bypass renal elimination entirely.
D. Discontinue the medication because aminoglycosides are contraindicated in all stages of CKD.
Correct Answer: A
Rationale:
In CKD, gentamicin clearance is reduced due to decreased glomerular filtration. Extending the dosing interval while
maintaining or slightly reducing the dose prevents nephrotoxicity while preserving efficacy. Shortening the interval (B)
would cause accumulation and toxicity. Oral aminoglycosides (C) are not absorbed systemically. Aminoglycosides are not
absolutely contraindicated (D) but require careful monitoring.
Q2 Question 2 of 50
A 45-year-old woman taking phenytoin for seizure control presents with nystagmus, ataxia, and
confusion. Her serum phenytoin level is 28 mcg/mL. The nurse practitioner recognizes that
phenytoin exhibits zero-order kinetics at therapeutic levels.
A. A small dose increase can produce a disproportionately large rise in serum concentration.
B. The drug is eliminated at a constant fraction per unit time regardless of concentration.
C. Steady-state concentration is reached within three to five half-lives at any dose.
D. Hepatic enzyme induction by phenytoin accelerates its own metabolism predictably.
Correct Answer: B
Rationale:
Phenytoin exhibits zero-order (capacity-limited) kinetics at therapeutic concentrations, meaning metabolic enzymes
become saturated. A small dose increase can cause a dramatic, disproportionate rise in serum levels. First-order kinetics
(A) apply at subtherapeutic doses. Steady-state (C) is unpredictable with zero-order kinetics. Autoinduction (D) occurs but
does not make metabolism predictable at saturation.
NR565 - 2026/2027 | Passing Score: 80% | Page 2 of 0
, Q3 Question 3 of 50
A 72-year-old patient with hepatic cirrhosis is prescribed lorazepam for anxiety. The nurse
practitioner selects this benzodiazepine over diazepam because of differences in metabolic
pathways that affect drug safety in liver disease.
A. Lorazepam undergoes glucuronidation, which remains relatively intact even with severe hepatic
impairment.
B. Lorazepam is metabolized exclusively by the kidneys and does not require hepatic processing.
C. Diazepam has a shorter half-life than lorazepam, making it less suitable for chronic anxiety.
D. Lorazepam is a prodrug that requires hepatic activation before becoming pharmacologically active.
Correct Answer: C
Rationale:
Lorazepam is metabolized primarily via glucuronidation, which is less affected by hepatic impairment compared to
oxidation pathways used by diazepam. In cirrhosis, oxidation is significantly impaired, causing diazepam accumulation
and prolonged sedation. Lorazepam is not renally eliminated (A). Diazepam has a longer half-life (B). Lorazepam is not a
prodrug (D).
Q4 Question 4 of 50
A 55-year-old patient on warfarin develops a urinary tract infection and is prescribed
trimethoprim-sulfamethoxazole. The nurse practitioner anticipates an increased risk of bleeding
because of a specific pharmacokinetic interaction.
A. Sulfamethoxazole displaces warfarin from albumin binding sites, increasing free drug concentration.
B. Trimethoprim inhibits CYP3A4, reducing warfarin metabolism and prolonging its half-life.
C. Sulfamethoxazole induces CYP2C9, accelerating warfarin clearance and reducing anticoagulant effect.
D. Trimethoprim increases renal excretion of warfarin, requiring dose escalation to maintain INR.
Correct Answer: D
Rationale:
Sulfamethoxazole is highly protein-bound and can displace warfarin from albumin, transiently increasing free (unbound)
warfarin and bleeding risk. Trimethoprim does not significantly inhibit CYP3A4 (B). Sulfamethoxazole does not induce
CYP2C9 (C); it may actually inhibit it. Trimethoprim does not increase warfarin renal excretion (D is correct).
NR565 - 2026/2027 | Passing Score: 80% | Page 3 of 0
OBJECTIVE ASSESSMENT - EXAM
NR565 Midterm Exam Review:
Advanced Pharmacology Care
of the Fundamentals
Questions and Answers (2026/2027) (Verified Answers) - Chamberlain
50 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
o Pharmacokinetics & Dynamics o Infectious Disease Therapy
o Cardiovascular Pharmacology o Neuropsychiatric Pharmacology
o Endocrine & Metabolic Agents o Pain Management Principles
COVER PAGE - 1
,SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q10 | NR565 2026/2027
SECTION 1
Q1 Question 1 of 50
A 68-year-old male with chronic kidney disease (CrCl 28 mL/min) is prescribed gentamicin for a
severe gram-negative infection. The prescriber asks the nurse practitioner to determine the
appropriate dosing interval adjustment based on altered pharmacokinetics.
A. Increase the dose and extend the interval to maintain therapeutic peak and trough levels.
B. Maintain the standard dose but shorten the interval to compensate for reduced clearance.
C. Switch to oral administration to bypass renal elimination entirely.
D. Discontinue the medication because aminoglycosides are contraindicated in all stages of CKD.
Correct Answer: A
Rationale:
In CKD, gentamicin clearance is reduced due to decreased glomerular filtration. Extending the dosing interval while
maintaining or slightly reducing the dose prevents nephrotoxicity while preserving efficacy. Shortening the interval (B)
would cause accumulation and toxicity. Oral aminoglycosides (C) are not absorbed systemically. Aminoglycosides are not
absolutely contraindicated (D) but require careful monitoring.
Q2 Question 2 of 50
A 45-year-old woman taking phenytoin for seizure control presents with nystagmus, ataxia, and
confusion. Her serum phenytoin level is 28 mcg/mL. The nurse practitioner recognizes that
phenytoin exhibits zero-order kinetics at therapeutic levels.
A. A small dose increase can produce a disproportionately large rise in serum concentration.
B. The drug is eliminated at a constant fraction per unit time regardless of concentration.
C. Steady-state concentration is reached within three to five half-lives at any dose.
D. Hepatic enzyme induction by phenytoin accelerates its own metabolism predictably.
Correct Answer: B
Rationale:
Phenytoin exhibits zero-order (capacity-limited) kinetics at therapeutic concentrations, meaning metabolic enzymes
become saturated. A small dose increase can cause a dramatic, disproportionate rise in serum levels. First-order kinetics
(A) apply at subtherapeutic doses. Steady-state (C) is unpredictable with zero-order kinetics. Autoinduction (D) occurs but
does not make metabolism predictable at saturation.
NR565 - 2026/2027 | Passing Score: 80% | Page 2 of 0
, Q3 Question 3 of 50
A 72-year-old patient with hepatic cirrhosis is prescribed lorazepam for anxiety. The nurse
practitioner selects this benzodiazepine over diazepam because of differences in metabolic
pathways that affect drug safety in liver disease.
A. Lorazepam undergoes glucuronidation, which remains relatively intact even with severe hepatic
impairment.
B. Lorazepam is metabolized exclusively by the kidneys and does not require hepatic processing.
C. Diazepam has a shorter half-life than lorazepam, making it less suitable for chronic anxiety.
D. Lorazepam is a prodrug that requires hepatic activation before becoming pharmacologically active.
Correct Answer: C
Rationale:
Lorazepam is metabolized primarily via glucuronidation, which is less affected by hepatic impairment compared to
oxidation pathways used by diazepam. In cirrhosis, oxidation is significantly impaired, causing diazepam accumulation
and prolonged sedation. Lorazepam is not renally eliminated (A). Diazepam has a longer half-life (B). Lorazepam is not a
prodrug (D).
Q4 Question 4 of 50
A 55-year-old patient on warfarin develops a urinary tract infection and is prescribed
trimethoprim-sulfamethoxazole. The nurse practitioner anticipates an increased risk of bleeding
because of a specific pharmacokinetic interaction.
A. Sulfamethoxazole displaces warfarin from albumin binding sites, increasing free drug concentration.
B. Trimethoprim inhibits CYP3A4, reducing warfarin metabolism and prolonging its half-life.
C. Sulfamethoxazole induces CYP2C9, accelerating warfarin clearance and reducing anticoagulant effect.
D. Trimethoprim increases renal excretion of warfarin, requiring dose escalation to maintain INR.
Correct Answer: D
Rationale:
Sulfamethoxazole is highly protein-bound and can displace warfarin from albumin, transiently increasing free (unbound)
warfarin and bleeding risk. Trimethoprim does not significantly inhibit CYP3A4 (B). Sulfamethoxazole does not induce
CYP2C9 (C); it may actually inhibit it. Trimethoprim does not increase warfarin renal excretion (D is correct).
NR565 - 2026/2027 | Passing Score: 80% | Page 3 of 0
